VASOTEC IV SOLUTION

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

ENALAPRILAT

Inapatikana kutoka:

SANDOZ CANADA INCORPORATED

ATC kanuni:

C09AA02

INN (Jina la Kimataifa):

ENALAPRIL

Kipimo:

1.25MG

Dawa fomu:

SOLUTION

Tungo:

ENALAPRILAT 1.25MG

Njia ya uendeshaji:

INTRAVENOUS

Vitengo katika mfuko:

2ML

Dawa ya aina:

Prescription

Eneo la matibabu:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0118001001; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2008-04-03

Tabia za bidhaa

_ _
VASOTEC
®
IV
Page 1 of 30
PRODUCT MONOGRAPH
Pr
VASOTEC
® IV
ENALAPRILAT INJECTION
1.25 MG/ML IN 2 ML VIALS
ANGIOTENSIN CONVERTING ENZYME INHIBITOR
Sandoz Canada Inc.
Date of Revision: September 20, 2013
145 Jules-Léger
Boucherville, QC, Canada
J4B 7K8
SUBMISSION CONTROL NO: 167061
_ _
VASOTEC
®
IV
Page 2 of 30
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................................
3
SUMMARY
PRODUCT
INFORMATION
..............................................................................................................
3
INDICATIONS
AND
CLINICAL
USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
3
WARNINGS
AND
PRECAUTIONS
........................................................................................................................
4
ADVERSE
REACTIONS
.........................................................................................................................................
7
DRUG
INTERACTIONS
........................................................................................................................................
13
DOSAGE
AND
ADMINISTRATION
....................................................................................................................
14
OVERDOSAGE
......................................................................................................................................................
15
ACTION
AND
CLINICAL
PHARMACOLOGY
...................................................................................................
15
STORAGE
AND
STABILITY
................................................................................................................................
17
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING
...........................